{"filing":{"accession_number":"0001493152-26-025037","cik":"0001541157","ticker":"AKTX","company_name":"Akari Therapeutics Plc","form":"8-K","filing_date":"2026-05-22","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315226025037/form8-k.htm"},"events":[{"id":10674,"run_id":9362,"accession_number":"0001493152-26-025037","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Akari Therapeutics entered into a securities purchase agreement on May 20, 2026 to sell 1,470,588 unregistered ADSs (or pre-funded warrants) plus multiple series of warrants in a private placement for approximately $5.5 million gross proceeds. This unregistered equity issuance under Section 4(a)(2) and Regulation D includes significant warrant coverage that will further dilute shareholders upon exercise.","company_name":"Akari Therapeutics Plc","ticker":"AKTX","filing_date":"2026-05-22","form":"8-K","submitted_at":null,"items":[{"id":7048,"accession_number":"0001493152-26-025037","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Akari Therapeutics entered into a securities purchase agreement on May 20, 2026 to sell 1,470,588 unregistered ADSs (or pre-funded warrants) plus multiple series of warrants in a private placement for approximately $5.5 million gross proceeds. This is a classic dilutive issuance of unregistered equity securities under Section 4(a)(2) and Regulation D, with significant warrant coverage that will further dilute shareholders upon exercise. The transaction is material to investors assessing the company's capital structure and ownership dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:55:52.361135+00:00","company_name":"","ticker":null,"filing_date":""},{"id":7049,"accession_number":"0001493152-26-025037","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 3.02 explicitly discloses unregistered sales of equity securities and incorporates by reference Item 1.01 details. Unregistered equity issuances are typically dilutive private placements or similar offerings that materially affect shareholder equity and are significant to investors assessing capital structure and dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:55:52.361135+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7048,"accession_number":"0001493152-26-025037","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Akari Therapeutics entered into a securities purchase agreement on May 20, 2026 to sell 1,470,588 unregistered ADSs (or pre-funded warrants) plus multiple series of warrants in a private placement for approximately $5.5 million gross proceeds. This is a classic dilutive issuance of unregistered equity securities under Section 4(a)(2) and Regulation D, with significant warrant coverage that will further dilute shareholders upon exercise. The transaction is material to investors assessing the company's capital structure and ownership dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:55:52.361135+00:00","company_name":"Akari Therapeutics Plc","ticker":"AKTX","filing_date":"2026-05-22"},{"id":7049,"accession_number":"0001493152-26-025037","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 3.02 explicitly discloses unregistered sales of equity securities and incorporates by reference Item 1.01 details. Unregistered equity issuances are typically dilutive private placements or similar offerings that materially affect shareholder equity and are significant to investors assessing capital structure and dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:55:52.361135+00:00","company_name":"Akari Therapeutics Plc","ticker":"AKTX","filing_date":"2026-05-22"}]}